|Day Low/High||138.17 / 154.85|
|52 Wk Low/High||117.34 / 497.49|
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Plus, why shares of vaccine maker Moderna are taking a hit.
Here is a summary of this week's major macroeconomic events: The Positives 1) Moderna , while still having to progress thru phase 3 trials, reported positive antibody results from phase 1 data and brings us a step closer to that hoped for vaccine....
All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.
FAANG stocks lag while the Russell rises, bringing divergences and questions.
A Fed governor speaks of accommodation, and AMC Entertainment's bond maneuvers serve as a warning to those who swim in the high-yield pool.
* Much like the Wild West, the market's action has turned unpredictable and volatile -- with little of a thematic character, save trading within a defined range and with some outstanding (and speculative) characters. The encouraging announcement of ...
Stock picking continues to be the most productive approach as market timers are battered and bruised once again.
This is pretty much exactly what you get when you have so much positive research.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
The extent of the measures taken to combat the virus seem to be an overreaction, and no one should count on a vaccine being a magic bullet.
What if the market is simply pricing in a quarter that had already been priced out?
I would wait until the next down day, and there will be one.
Plus, a closer look at Thursday's late-day rally and at actions impacting the nation's big banks.
The charts of the electric vehicle maker are showing some weakening in the stock, though a major shake-out isn't likely.
Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?
I can't educate the foreign investors. The professional mutual fund managers think I'm dead wrong. But I can help teach the new retail traders.
This market is offering trading opportunities the likes of which haven't been seen since early 2009.
The massive tock market drop was to be expected, and seasoned traders were prepared for it. But there was also some good news on the coronavirus vaccine/treatment front.
The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.
Let's hope that the violence subsides, the valid voices of peaceful protesters are heard, and the lack of social distancing protocols does not lead to a resurgence in the spread of the virus.
A now-overbought market leaves few values available among equities.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
The negatives are being shaken off like a first time rider on a long-time bull which means long remains the name of the game.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
The market may be down but, once again, the decline's about the White House getting re-tough on China.